Protein Summary
In complex with TSC1, this tumor suppressor inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling (PubMed:12271141, PubMed:28215400). Acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1 (PubMed:15340059). May also play a role in microtubule-mediated protein transport (By similarity). Also stimulates the intrinsic GTPase activity of the Ras-related proteins RAP1A and RAB5 (By similarity). Mutations in this gene lead to tuberous sclerosis complex. Its gene product is believed to be a tumor suppressor and is able to stimulate specific GTPases. The protein associates with hamartin in a cytosolic complex, possibly acting as a chaperone for hamartin. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]
- ENST00000219476
- ENSP00000219476
- ENSG00000103197
- ENST00000350773
- ENSP00000344383
- ENST00000382538
- ENSP00000371978
- ENST00000401874
- ENSP00000384468
- ENST00000439673
- ENSP00000399232
- ENST00000642936
- ENSP00000494514
- ENST00000644043
- ENSP00000496262
- TSC4
- LAM
- TSC4
- PPP1R160
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
hub protein | 1 | ||
biological process | 0.99 | ||
biological term | 0.98 | ||
disease perturbation | 0.9 | ||
kinase | 0.9 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1830.65 (req: < 5)
Gene RIFs: 343 (req: <= 3)
Antibodies: 1854 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1830.65 (req: >= 5)
Gene RIFs: 343 (req: > 3)
Antibodies: 1854 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 29
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0